Share |

Content about Northwest Biotherapeutics

August 12, 2011

Bethesda-based Northwest Biotherapeutics (OTC: NWBO) released a statement to give surety to Investors that its DCVax drug, will not run into the same issues currently facing Seattle, Washington-based, Dendreon Corporation's (NASDAQ:DNDN) Provenge immune therapy drug.

July 10, 2011

The Richard M. Schulze Foundation made an equity investment in Bethesda based Northwest Biotherapeutics, Inc.

The microcap biotech received $4.55 million from the foundation on June 28th, 2011.

Currently in Phase III of its leading drug DCVax -Prostate, as the name implies, the treatment was developed as a new way to battle prostate cancer.

 Northwest focuses on creating treatments using personalized medicine techniques, the company moved to Montgomery County, Maryland from the Seattle, Washington area in 2007.